ABOUT US
Proven track record of bringing new therapies to patients
The Navigator leadership and Navigator crew have successfully steered the development of multiple new treatments for inflammatory disorders and autoimmune diseases. We understand what it takes to advance science from research to remedy to help people living with difficult to treat conditions and are working at pace to bring meaningful new therapies to patients as quickly as possible.
LEADERSHIP TEAM
Tausif ‘Tosh’ Butt
CEO and President
Dana McClintock, MD
Chief Medical Officer
Kristie Grebe, PhD
Chief Scientific Officer
BOARD OF DIRECTORS
Our Board of Directors, comprised of biotech and venture capital leaders, bring deep expertise and strong governance as we navigate the next phase of our pipeline development and company growth.
Khurem Farooq, MBA - Board Chair
Co-Founder and CEO, Verdiva Bio
Wouter Joustra, MBA
General Partner, Forbion
Andrew Levin, PhD, MD
Partner and Managing Director,
RA Capital Management
Stephen Thomas, PhD
Co-Founder and CEO, Sera Medicine
INVESTORS
We are proud to partner with impact-driven premier investors who are committed to helping realize the potential of OX40L bispecific antibody development for inflammatory disorders and autoimmune disease.
